嵌合抗原受体 T 细胞在骨髓微环境中与骨髓瘤作斗争。
CAR T Cells Contend with Myeloma in the Bone Marrow Microenvironment.
机构信息
Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
出版信息
Blood Cancer Discov. 2022 Nov 2;3(6):478-480. doi: 10.1158/2643-3230.BCD-22-0126.
Abstract
In this issue of Blood Cancer Discovery, Dhodapkar and colleagues find that myeloid, dendritic, and endogenous T-cell populations in the bone marrow microenvironment are associated with progression-free survival (PFS) in multiple myeloma patients responding to B-cell maturation antigen-targeted CAR T cells. Immunosuppressive myeloid cells are associated with short PFS, but a diverse T-cell receptor repertoire and more dendritic cells are associated with a longer PFS, suggesting a potential role for epitope spreading. See related article by Dhodapkar et al., p. 490 (6).
摘要
在本期《Blood Cancer Discovery》中，Dhodapkar 及其同事发现，骨髓微环境中的髓样细胞、树突状细胞和内源性 T 细胞群体与接受 B 细胞成熟抗原靶向嵌合抗原受体 T 细胞治疗后多发性骨髓瘤患者的无进展生存期（PFS）相关。抑制性髓样细胞与 PFS 较短相关，但多样性 T 细胞受体库和更多的树突状细胞与 PFS 较长相关，这表明表位扩展可能发挥作用。见 Dhodapkar 等人的相关文章，第 490 页（6）。
相似文献
1
CAR T Cells Contend with Myeloma in the Bone Marrow Microenvironment.嵌合抗原受体 T 细胞在骨髓微环境中与骨髓瘤作斗争。
Blood Cancer Discov. 2022 Nov 2;3(6):478-480. doi: 10.1158/2643-3230.BCD-22-0126.
2
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.骨髓肿瘤和免疫细胞的变化与骨髓瘤患者接受 BCMA CAR T 治疗后的缓解持续时间相关。
Blood Cancer Discov. 2022 Nov 2;3(6):490-501. doi: 10.1158/2643-3230.BCD-22-0018.
3
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.表达抗B细胞成熟抗原嵌合抗原受体的T细胞可使多发性骨髓瘤缓解。
Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.
4
Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy.骨髓微环境在使用嵌合抗原受体T细胞（CAR-T）疗法治疗多发性骨髓瘤中的作用。
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(8):807-815. doi: 10.1080/14737140.2023.2229029. Epub 2023 Jun 27.
5
Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.双特异性嵌合抗原受体 T 细胞治疗多发性骨髓瘤。
Cancer Immunol Res. 2020 Dec;8(12):1485-1495. doi: 10.1158/2326-6066.CIR-20-0118. Epub 2020 Oct 2.
6
B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.基于 B 细胞成熟抗原 (BCMA) 的多发性骨髓瘤免疫疗法。
Expert Opin Biol Ther. 2019 Nov;19(11):1143-1156. doi: 10.1080/14712598.2019.1641196. Epub 2019 Jul 11.
7
Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.嵌合抗原受体修饰 T 细胞疗法在多发性骨髓瘤中的应用：超越 B 细胞成熟抗原。
Front Immunol. 2019 Jul 16;10:1613. doi: 10.3389/fimmu.2019.01613. eCollection 2019.
8
B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.嵌合抗原受体 T 细胞治疗复发或难治性多发性骨髓瘤的 B 细胞成熟抗原特异性：一项荟萃分析。
Eur J Haematol. 2020 Apr;104(4):318-327. doi: 10.1111/ejh.13380. Epub 2020 Jan 20.
9
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.同种异体嵌合抗原受体 T 细胞靶向 BCMA 治疗多发性骨髓瘤的临床前评估。
Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
10
CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.用于治疗多发性骨髓瘤的靶向B细胞成熟抗原的嵌合抗原受体T细胞疗法
Clin Adv Hematol Oncol. 2018 Dec;16(12):804-806.
引用本文的文献
1
Deciphering the response to BCMA CAR T cell therapy.解读对BCMA嵌合抗原受体T细胞疗法的反应。
Nat Cancer. 2024 Sep;5(9):1287-1288. doi: 10.1038/s43018-024-00826-w.
本文引用的文献
1
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.骨髓肿瘤和免疫细胞的变化与骨髓瘤患者接受 BCMA CAR T 治疗后的缓解持续时间相关。
Blood Cancer Discov. 2022 Nov 2;3(6):490-501. doi: 10.1158/2643-3230.BCD-22-0018.
2
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.西达基奥仑赛，一种抗 B 细胞成熟抗原嵌合抗原受体 T 细胞疗法，用于治疗复发/难治性多发性骨髓瘤：CARTITUDE-1 研究 2 年随访结果。
J Clin Oncol. 2023 Feb 20;41(6):1265-1274. doi: 10.1200/JCO.22.00842. Epub 2022 Jun 4.
3
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma.靶向骨髓中的癌相关成纤维细胞可预防多发性骨髓瘤对 CART 细胞治疗的耐药性。
Blood. 2022 Jun 30;139(26):3708-3721. doi: 10.1182/blood.2021012811.
4
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛，一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法，用于治疗复发或难治性多发性骨髓瘤患者（CARTITUDE-1）：一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
5
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis.骨髓间充质基质细胞可通过抑制细胞凋亡使多发性骨髓瘤细胞对 CAR T 细胞的细胞毒性机制产生耐药性。
Clin Cancer Res. 2021 Jul 1;27(13):3793-3803. doi: 10.1158/1078-0432.CCR-20-2188. Epub 2021 Apr 21.
6
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
7
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.双等位基因 BCMA 缺失导致多发性骨髓瘤患者对 CAR T 细胞治疗产生耐药。
Nat Commun. 2021 Feb 8;12(1):868. doi: 10.1038/s41467-021-21177-5.
8
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.B 细胞成熟抗原特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中具有临床活性。
J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397.
Zotero 插件